Trending...
- Terri Ross, Renowned Practice Consultant, Joins Dozens of Industry Thought Leaders to Speak at the ISAPS Business School Program
- #1 Billboard Jazz Artist Ski Johnson to Release 10th Studio Album and Tell All Movie
- Potentially Dangerous Flaw Found in Clean-Air Installations Across America
MILWAUKEE, April 6, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Acadia (NASDAQ: ACAD). The investigation results from inaccurate statements Acadia may have made regarding its financial results, business operations and prospects.
Click here to learn more about the investigation: https://www.ademilaw.com/case/acadia-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on whether Acadia properly disclosed the facts underlying its supplemental new drug application for NUPLAZID® (pimavanserin), which is used for the treatment of hallucinations and delusions associated with dementia. On March 8, Acadia announced that the FDA had "identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time" with respect to its NUPLAZID® application. On April 5, Acadia announced that the FDA had rejected the NUPLAZID® application because it lacks substantial evidence of effectiveness to support approval.
More on Wisconsin Eagle
If you wish to obtain additional information or have information about this investigation, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, https://www.ademilaw.com/case/acadia-pharmaceuticals-inc.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Ademi LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com
SOURCE Ademi LLP
Related Links
http://www.ademilaw.com
Click here to learn more about the investigation: https://www.ademilaw.com/case/acadia-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
The investigation focuses on whether Acadia properly disclosed the facts underlying its supplemental new drug application for NUPLAZID® (pimavanserin), which is used for the treatment of hallucinations and delusions associated with dementia. On March 8, Acadia announced that the FDA had "identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time" with respect to its NUPLAZID® application. On April 5, Acadia announced that the FDA had rejected the NUPLAZID® application because it lacks substantial evidence of effectiveness to support approval.
More on Wisconsin Eagle
- Church Mutual Receives National Attention for Culture Transformation
- A Urban Morgan Productions Inc. debuts its latest feature film "Deception," directed by Justin Williams
- Companies Can Now Get an Energy Manager on Their Staff but Not on Their Payroll
- New Website For Pop Art Phenomenon 'Whatshisname'
- Build remote and flexible Supply Chain solutions with Stockarea
If you wish to obtain additional information or have information about this investigation, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, https://www.ademilaw.com/case/acadia-pharmaceuticals-inc.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Ademi LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com
SOURCE Ademi LLP
Related Links
http://www.ademilaw.com
Filed Under: Business
0 Comments
Latest on Wisconsin Eagle
- Resolution Introduced in New York City Council Calls on the United States to Endorse United Nations Convention on Biological Diversity
- Absortech breaks new sustainable ground
- Inframark Acquires Environmental Development Partners
- ResortNet Completes Installation Of Fiber-To-The-Home (FTTH) to Rural Colorado Residential Community
- Womxn of Color Summit's The Art of Authentic Living Brought Over 350 Women of Color and Non-Binary People of Color Together to Heal in Community
- A Timeless $14 Million, Mediterranean Villa is one of the Highest-Priced Listings In Tampa
- National Association of Tax Professionals announces sessions in virtual education event
- Shareholder Alert: Ademi LLP investigates whether Knoll Inc. has obtained a Fair Price in its transaction with Herman Miller, Inc.
- WHO-Compliant, FDA-approve Quantum-ION® Long-lasting, Contactless, Antimicrobial Protection
- Sandline Welcomes Trusted Forensic Expert & Advisor Robert B. Fried
- Children's author releases first book in the Nick series
- HomeCentris Healthcare Announces Expansion into Pennsylvania
- B Martin Launches "Purpose Driven Artists" Record Label To Create Songs That Heal
- Parvati Foundation Leads Arctic Free To Save The World
- The 2021 Property Tax Base of the City of Madison
- Cape Coral, Fort Myers, Naples Real Estate Broker CEO Is Concerned About The 17 Million Americans Behind on Their Mortgage Payments
- Madison: Beyond the Page and Dane County Libraries seeking applications for year of programming around themes of race and equity
- hellowater®, the Water That Works™ brand launches hellowater Defense power by CYTO+
- Celebrate Golden Week in Tokyo with 1,000 Colorful Carp Streamers
- Viva Tequila Festival Mexico Experience Tour Honored at Taste Awards in the Outstanding Culinary & Travel Experience Category